Thermo Fisher Scientific [NYSE: TMO]

Jonathan Aceves

Clinical Quality Steward

Regulatory Strategy Perspective for Life Sciences

For years, clinical research has moved faster than the rules meant to guide it. We are running decentralized and hybrid trials and collecting data through wearables and apps, yet many audits still rely on expectations written for paper CRFs and on-site monitoring. With ICH E6 Revision 3 (E6(R3)), that gap finally begins to close. This revision is more than a technical update. It is a deliberate effort to bring GCP in line with the way modern trials are designed and carried out.

At the center of E6(R3) is a shift from prescriptive checklists to a principles-based, risk-focused model. Instead of assuming that all trials carry the same level of risk and require the same oversight, the guideline asks sponsors to identify what is critical to quality for each study and to build controls around those elements. This approach fits the current landscape, where complex designs, precision medicine and fast-moving programs need both speed and reliability.

This is where quality by design becomes a working method rather than a slogan. Under E6(R3), quality is not something inspected at the end. It is built into the protocol and operational plan from the start. Sponsors are expected to define critical-to-quality factors, assess the risks that threaten them and set quality tolerance limits that trigger investigation and mitigation when crossed. For organizations already moving toward risk-based quality management, the guideline supplies a shared framework.

E6(R3) is also written with decentralized and hybrid trials in mind, even if the text avoids naming them directly. It is technology-neutral, but it recognizes that assessments may occur outside traditional sites, that data may come from eSource, ePRO, sensors or home visits and that monitoring may combine on-site, remote and centralized approaches. Instead of forcing innovative designs into older structures, it offers expectations that work whether a visit happens in a clinic, at a participant’s home or through telemedicine.

The guideline also strengthens expectations around data governance and digital systems. Today’s trials depend on a broad mix of platforms, including EDC, eCOA, eConsent, randomization tools and data hubs for imaging and wearables. E6(R3) acknowledges this reality and requires that systems be validated in proportion to their risk, support complete audit trails and protect data that are attributable, legible, contemporaneous, original and accurate. The focus is on sound data integrity rather than a single validation model for every tool.

The relationship between sponsors, CROs and specialized vendors is another area where the guideline reflects current practice. Development has become more outsourced and modular, with niche providers for digital recruitment, remote assessments and data science. E6(R3) accepts this structure but reinforces a simple rule. Responsibility cannot be outsourced. The sponsor remains accountable for participant safety and data quality, even when work is delegated.

A forward-looking element of the guideline is the way it accommodates artificial intelligence and advanced analytics without naming them. Any AI used in trial operations must follow familiar GCP principles: proportional risk management, validated performance, transparency and human oversight. This matches how leading organizations are beginning to use AI, whether for monitoring prioritization, anomaly detection, adherence support or early drafting of protocols and narratives under human review. The guideline makes clear that if a tool influences trial conduct or data, it belongs inside the quality system.

E6(R3) also echoes a broader cultural shift, moving away from “do everything, just in case” toward “do what matters and explain why.” With tighter timelines and increasing complexity, the older model of exhaustive monitoring and documentation is no longer sustainable. The guideline’s emphasis on proportionate oversight opens space for innovation, but it also requires stronger reasoning and documentation around design choices, risk acceptance and mitigation decisions.

For life science organizations, the message is direct. E6(R3) is not a barrier to innovation. It is the common language that connects innovation with compliance. It validates decentralized and digital trial models, codifies risk-based and data-driven oversight and provides a stable regulatory frame within which AI can be used responsibly. The companies that will benefit most are those that see this revision as more than an SOP change. It is an opportunity to redesign how they approach quality, risk and technology across the trial lifecycle.

ICH E6(R3) is the moment where regulation finally catches up with the future of clinical trials. The key question is no longer “Will the guideline allow us to do this?” but “How will we use this new flexibility to build smarter, more patient-centric, and more trustworthy research?”